Analyst Price Targets — NGEN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 8, 2026 7:18 pm | — | Maxim Group | $12.00 | $4.18 | TheFly | NervGen Pharma price target raised to $12 from $10 at Maxim |
Latest News for NGEN
VANCOUVER, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that Adam Rogers, MD, President and Chief Executive Officer of NervGen, and other members of…
VANCOUVER, British Columbia, April 07, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced the completion of a successful End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug…
VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today reported its full year 2025 financial results and provided business updates.
NervGen Pharma Corp. demonstrates lasting functional improvements in chronic cervical spinal cord injury patients with NVG-291, supporting its unique regenerative approach. NGEN's regulatory engagement is strong, with expedited FDA pathways under discussion and a Phase 3 trial for up to 150 patients set to begin this summer. Recent $10M private investment and prior ATM sales provide near-term funding, but additional…
VANCOUVER, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that the Company has elected to voluntarily delist its common shares from TSX…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NGEN.
U.S. House Trading
No House trades found for NGEN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.